Comparison of first refill rates among users of sertraline, paroxetine, and citalopram

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 297-305

  Mullins, C Daniel ^a   Shaya, Fadia T ^a   Meng, Fanlun ^a   Wang, Junling ^b   Bron, Morgan S ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^c PFIZER INC   (United States)

Author keywords

adherence; cost; discontinuation; pharmacotherapy; refill; selective serotonin reuptake inhibitor; SSRI

Indexed keywords

CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; COMPARATIVE STUDY; DATA BASE; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; SOCIAL PHOBIA; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CITALOPRAM; COHORT STUDIES; COST SHARING; DATABASES, FACTUAL; DEPRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAROXETINE; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; UNITED STATES;

EID: 33646179331     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.02.006     Document Type: Article

References (34)

1. Davis R., Wilde M., and Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 10 (1996) 409-431
2. Cutler J., and Charon R. Depression. In: Feinstein R., and Brewer A. (Eds). Primary Care Psychiatry and Behavioral Medicine: Brief Office Treatment and Management Pathways (1999), Springer, New York, NY 55-82
3. Jones M., and Cockrum P. A critical review of published economic modelling studies in depression. Pharmacoeconomics 17 (2000) 555-583
4. Hirschfeld R., Keller M., Panico S., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277 (1997) 333-340
5. Solnek B., and Seiter T. How to diagnose and treat depression. Nurse Pract 27 (2002) 12-24
6. Available at. World Health Organization. Depression. What is depression?. Accessed July 29, 2004. http://www.who.int/mental_health/manageemnt/depression/definition/en/
7. Greenberg P., Stiglin L., Finkelstein S., and Berndt E. The economic burden of depression in 1990. J Clin Psychiatry 54 (1993) 405-418
8. Greenberg P., Kessler R., Birnbaum H., et al. The economic burden of depression in the United States: How did it change between 1990 and 2000. J Clin Psychiatry 64 (2003) 1465-1475
9. Lin E., Von Korff M., Katon W., et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 33 (1995) 67-74
10. Linden M., Gothe H., Dittmann R., and Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 20 (2000) 523-530
11. Bull S., Hunkeler E., Lee J., et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36 (2002) 578-584
12. Wahl C., Gregoire J., Teo K., et al. Concordance, compliance and adherence in healthcare: Closing gaps and improving outcomes. Healthe Q. 8 (2005) 65-70
13. Lewis E., Marcus S., Olfson M., et al. Patients' early discontinuation of antidepressant prescriptions. Psychiatr Serv 55 (2004) 494
14. Simon G., VonKoff M., Wagner E., and Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 15 (1993) 399-408
15. Katon W., von Korff M., Lin E., et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 30 (1992) 67-76
16. Melfi C., Chawla A., Croghan T., et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55 (1998) 1128-1132
17. Claxton A., Li Z., and McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression. Br J Psychiatry 177 (2000) 163-168
18. Mullins C., Shaya F., Meng F., et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25 (2005) 660-667
19. Weycker D., Akhras K., Edelsberg J., et al. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 31 (2003) 2316-2323
20. International Classification of Diseases, Ninth Revision, Clinical Modification. 6th ed. (2003), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Washington, DC
21. Motheral B., and Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care 5 (1999) 1383-1394
22. Available at. American Psychiatric Association. Part A: Treatment recommendations for patients with major depressive disorder. Accessed November 7, 2005. http://www.psych.org/psych_pract/treatg/pg/Depression2e.book/7.cfm#b
23. Fawcett J. Compliance: Definitions and key issues. J Clin Psychiatry 56 Suppl 1 (1995) 4-10
24. Kaplan E. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry 58 Suppl 7 (1997) 31-36
25. Polsky D., Onesirosan P., Bauer M., and Glick H. Duration of therapy and health carecosts of fluoxetine, paroxetine, and sertraline in 6 health plants. J Clin Psychiatry 63 (2002) 156-164
26. Gevirtz F., Way K., Young C., et al. SSRI-to-SSRI switching and associated dosing characteristics. J Manag Care Pharm 5 (1999) 138-143
27. Weilburg J., Stafford R., O'Leary K., et al. Costs of antidepressant medications associated with inadequate treatment. Am J Manag Care 10 (2004) 357-365
28. Abstract. Hinkes R., and Alvarez M. Adherence to antidepressant therapy in an outpatient psychiatric population. Program and abstracts of the ASHP Annual Meeting. Los Angeles, Calif. (June 3-6, 2001)
29. Nurnberg H., Thompson P., and Hensley P. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 60 (1999) 574-579
30. Hylan T., Crown W., Meneades L., et al. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. Med Care 37 4 Suppl Lilly (1999) AS36-AS44
31. Thomas C. Incentive-based formularies. N Engl J Med 349 (2003) 2186-2188
32. Strunk B., and Reschovsky J. Kinder and gentler: Physicians and managed care, 1997-2001. Track Rep. 5 (2002) 1-4
33. Huskamp H., Deverka P., Epstein A., et al. The effect of incentivebased formularies on prescriptiondrug utilization and spending. N Engl J Med 349 (2003) 2224-2232
34. Frank R., Huskamp H., and Pincus H. Aligning incentives in the treatment of depression in primary care with evidence-based practice. Psychiatr Serv 54 (2003) 682-687